What Is Kisspeptin-10? Definition and What Research Reports
Kisspeptin-10 is a ten-amino-acid fragment of the larger kisspeptin protein encoded by the KISS1 gene. It binds the receptor KISS1R (also called GPR54) and, in published research, acts upstream of the hypothalamic–pituitary–gonadal axis. Reviews describe kisspeptin signalling as a link between energy balance and reproduction, and separate studies examined prolactin, glucose handling, bone cells and blood–brain barrier models. It is a research and anti-doping analytical target, not an approved medicine.
Plain definition
Kisspeptin-10 is the name given to a short ten-amino-acid piece of a larger natural signalling protein called kisspeptin, which the body makes from the KISS1 gene. The ten-amino-acid piece is the smallest fragment that still switches on kisspeptin's receptor, so laboratories use it as a compact, synthesisable stand-in for the full-length molecule. In the published literature, kisspeptin signalling sits at the top of the reproductive hormone cascade: it acts on neurons in the hypothalamus that release gonadotropin-releasing hormone (GnRH), which in turn influences the pituitary hormones LH and FSH. Reviews of the field describe kisspeptin as a central gatekeeper of that axis (PMID 35837314). Kisspeptin-10 is a laboratory and clinical-research reagent, not an approved therapeutic product.
What kisspeptin-10 is in biochemical terms
The KISS1 gene product is processed into peptides of differing lengths that share a common C-terminal region. Kisspeptin-10 corresponds to that shared C-terminal decapeptide, which is why it retains agonist activity at the receptor KISS1R — written in much of the animal literature as GPR54 or Gpr54. KISS1R is a G-protein-coupled receptor, meaning activation triggers intracellular second-messenger cascades rather than direct hormone release from the peptide itself. Reviews of receptor pharmacology and downstream signalling in the hypothalamic–pituitary–gonadal (HPG) axis summarised this arrangement and the role of kisspeptin neuron populations in the arcuate nucleus and preoptic area (PMID 35837314). A 2022 pharmacology review catalogued the receptor-targeting approaches — agonists, antagonists and analogues — being explored across reproductive and non-reproductive indications (PMID 36413854).
Because kisspeptin-10 is a short, unmodified peptide, it is also short-lived in biological fluids. That property matters for analytical chemistry: a 2024 method paper described detecting kisspeptin-10 in urine using liquid chromatography high-resolution mass spectrometry, and the authors framed the peptide explicitly as doping-relevant — that is, a substance anti-doping laboratories need assays for (PMID 38978171).
Related terms and how they differ
| Term | What it refers to |
|---|---|
| KISS1 / KISS1 gene | The gene encoding the precursor protein from which kisspeptin peptides are derived. |
| Kisspeptin (generic) | The family of peptides from that precursor; used loosely in reviews to mean the signalling system as a whole. |
| Kisspeptin-54 | The longer peptide form; historically also called metastin in cancer-biology papers. |
| Kisspeptin-10 | The C-terminal decapeptide fragment; the form most often synthesised for research. |
| KISS1R / GPR54 | The receptor kisspeptin peptides bind; "GPR54" is the older name, still standard in rodent work (PMID 38346942). |
| KNDy neurons | Hypothalamic neurons co-expressing kisspeptin, neurokinin B and dynorphin, discussed in HPG-axis reviews (PMID 35837314). |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow the term is used in peptide research
In the scientific literature, "kisspeptin-10" almost always denotes a defined reagent used to probe receptor signalling — infused in animals, applied to cultured cells, or administered under controlled conditions in human physiology studies. Papers use it to ask mechanistic questions: which neurons respond, which second messengers are engaged, what happens when the receptor is absent. A 2023 mouse study used circuit-level tools to test whether kisspeptin neuron projections to oxytocin neurons were required for birth, and researchers reported that those projections were not necessary for parturition in the mouse — an example of the literature narrowing, rather than widening, claims about the system (PMID 37389617).
Expression studies form a second common use. A 2022 report characterised kisspeptin expression in the adult hamster testis, contributing to evidence that the system operates in peripheral reproductive tissues and not only in the brain (PMID 36285151).
Where the term is misused
- Treating "kisspeptin-10" and "kisspeptin" as interchangeable. Reviews cover a family of peptides, receptor subtypes and species differences; a claim about the system is not automatically a claim about the decapeptide.
- Reading animal or cell findings as human outcomes. Several of the most-cited mechanistic results come from mice, ewes, hamsters and cultured cells (PMID 38346942, PMID 29549187).
- Confusing agonist and antagonist findings. A 2018 study in ewes reported that kisspeptin antagonists stimulated growth hormone, meaning direction of effect depended on whether the receptor was blocked or activated (PMID 29549187).
- Calling it a fertility or libido "treatment". The published work is mechanistic and exploratory; a 2022 review described therapeutic avenues as novel and still under investigation (PMID 36413854).
- Ignoring its anti-doping status. Analytical chemists categorise it as a doping-relevant peptide requiring urine detection methods (PMID 38978171).
What the published literature reports
Reproductive axis
The most established theme is control of the HPG axis. A 2022 review in Frontiers in Endocrinology summarised evidence that kisspeptin signalling through KISS1R governs GnRH neuron activity and, downstream, gonadotropin secretion and reproductive function; loss-of-function in the system was associated with failure of normal pubertal activation (PMID 35837314).
Energy balance and metabolism
A 2020 Nature Reviews Endocrinology review framed kisspeptin as a molecular link between energy balance and reproduction, describing how nutritional and metabolic signals converge on kisspeptin neurons (PMID 32427949). A 2022 review in The Journal of Physiology covered emerging metabolic roles beyond reproduction, including actions at peripheral metabolic tissues (PMID 33977536). A 2019 review focused specifically on kisspeptin and glucose homeostasis, including signalling at pancreatic islets (PMID 31869842).
Prolactin
A companion 2019 review examined the relationship between kisspeptin and prolactin, a hormone that itself feeds back on reproductive signalling (PMID 31847029).
Bone cells
A 2024 Nature Communications paper moved outside classical endocrinology: researchers reported that kisspeptin-10 binding to Gpr54 on osteoclasts prevented bone loss, and the study attributed this to Dusp18-mediated dephosphorylation of Src within the osteoclast (PMID 38346942).
Neurovascular models
A 2025 Neurotoxicology paper reported that kisspeptin-10 protected against HIV-1 Tat-induced blood–brain barrier dysfunction and neuroinflammation in the models used, with the authors implicating the RhoA/ROCK pathway and discussing implications for HIV-associated neurocognitive disorders (PMID 40712838).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appAdverse Events and Safety Signals: What Studies Report
The verified literature summarised here is predominantly mechanistic — reviews of receptor biology, animal experiments, cell models and an analytical method paper — rather than safety trials designed to quantify adverse events. None of these papers established a tolerability profile for kisspeptin-10 in humans. The 2022 pharmacology review discussed therapeutic development as an open research area rather than a settled one, which is the appropriate frame for safety expectations (PMID 36413854). Reviews also noted that effects are context-dependent: because kisspeptin signalling intersects reproductive, prolactin and glucose-regulatory pathways, an intervention at the receptor is unlikely to act on one system in isolation (PMID 31847029, PMID 31869842). The 2018 ewe study is a reminder that blocking the receptor produced its own endocrine consequence, with growth hormone changes reported after antagonist administration (PMID 29549187).
Regulatory and status notes
Kisspeptin-10 is not an approved drug product in the United States; material sold to laboratories is typically labelled research use only, which is a supply-chain designation rather than a statement about human safety or efficacy. Its inclusion as a target in anti-doping urine assays indicates that sport-governing analytical programmes treat it as a substance worth screening for (PMID 38978171).
This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or hormone-related concern. Nothing here describes a protocol, and the summaries above report what each cited study or review stated within its own model and population.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction (Frontiers in Endocrinology, 2022)
- Metabolic regulation of kisspeptin - the link between energy balance and reproduction (Nature Reviews Endocrinology, 2020)
- Emerging roles for kisspeptin in metabolism (The Journal of Physiology, 2022)
- Kisspeptin and Glucose Homeostasis (Seminars in Reproductive Medicine, 2019)
- Kisspeptin and Prolactin (Seminars in Reproductive Medicine, 2019)
- Novel therapeutic avenues for kisspeptin (Current Opinion in Pharmacology, 2022)
- Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src (Nature Communications, 2024)
- Kisspeptin-10 protects against HIV-1 Tat-induced blood-brain barrier dysfunction and neuroinflammation via RhoA/ROCK pathway (Neurotoxicology, 2025)
- Stimulation of growth hormone by kisspeptin antagonists in ewes (The Journal of Endocrinology, 2018)
- Kisspeptin neuron projections to oxytocin neurons are not necessary for parturition in the mouse (Brain Structure & Function, 2023)
- Expression of Kisspeptin in the Adult Hamster Testis (Development & Reproduction, 2022)
- Investigating the detection of the novel doping-relevant peptide kisspeptin-10 in urine using liquid chromatography high-resolution mass spectrometry (Biomedical Chromatography, 2024)
Frequently asked questions
What does the "-10" in kisspeptin-10 mean?▾
It refers to the number of amino acids in the fragment. Kisspeptin peptides derived from the KISS1 precursor share a common C-terminal region, and the ten-residue version is the shortest form that still activates the receptor KISS1R, also called GPR54 in animal studies. Reviews of receptor biology describe this shared C-terminal requirement for signalling (PMID 35837314).
Which receptor does kisspeptin-10 act on?▾
KISS1R, a G-protein-coupled receptor written as GPR54 in much of the rodent literature. Reviews summarised its role in regulating GnRH neurons and the hypothalamic–pituitary–gonadal axis (PMID 35837314). A 2024 mouse-focused paper used the Gpr54 naming when researchers reported receptor binding on osteoclasts and a downstream Dusp18–Src signalling step (PMID 38346942).
Is kisspeptin-10 only involved in reproduction?▾
No. Reproduction is the best-characterised role, but reviews described kisspeptin as a link between energy balance and reproduction (PMID 32427949) and covered emerging metabolic roles including glucose homeostasis (PMID 33977536, PMID 31869842). Separate papers reported effects in osteoclast biology (PMID 38346942) and in blood–brain barrier models exposed to HIV-1 Tat (PMID 40712838).
Is kisspeptin-10 an approved medicine?▾
No. It is not an approved drug product; material supplied to laboratories is typically labelled research use only, a supply designation rather than a safety statement. A 2022 pharmacology review framed kisspeptin-directed therapeutics as novel avenues still under investigation (PMID 36413854). Anti-doping chemists also treat it as a screening target in urine testing (PMID 38978171).
Why do anti-doping laboratories test for kisspeptin-10?▾
Because it is classified as a doping-relevant peptide. A 2024 method paper described developing and investigating liquid chromatography high-resolution mass spectrometry detection of kisspeptin-10 in urine, which the authors presented as necessary analytical capability for sport testing programmes (PMID 38978171). The paper addressed detection methodology, not physiological effects or administration.
What did studies using kisspeptin antagonists report?▾
A 2018 study in ewes examined receptor blockade rather than activation, and researchers reported stimulation of growth hormone by kisspeptin antagonists (PMID 29549187). That result illustrates why agonist and antagonist findings should not be merged: direction of hormonal effect depended on whether the receptor was activated or blocked, and the work was conducted in sheep.
Do all kisspeptin findings translate from animals to humans?▾
Not automatically. Much of the mechanistic literature comes from mice, sheep, hamsters and cell models — for example, hamster testis expression work (PMID 36285151) and a mouse circuit study in which researchers reported that kisspeptin projections to oxytocin neurons were not necessary for parturition (PMID 37389617). Reviews of the field note species differences in kisspeptin signalling (PMID 35837314).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.